Liver Cancer
Advertisement
The TransMet trial was developed to determine the efficacy of chemotherapy with LT compared with chemotherapy alone.
ASCO has issued a companion piece to previously released guidelines addressing commonly asked questions.
A review analyzed 30 meta-analyses to determine the association between pretreatment NLR and immunotherapy outcomes.
Atezolizumab/bevacizumab and lenvatinib have both shown efficacy as first-line treatments for hepatocellular carcinoma.
A personalized therapeutic cancer vaccine may increase patient response to PD-1 inhibitors.
The study’s primary end points were objective response rate, overall survival, and safety.
The latest guideline update includes recommendations for first-, second-, and third-line therapy options.
Researchers investigated the potential of the phosphatidylserine-targeting antibody bavituximab plus pembrolizumab.
The CheckMate 040 trial reported that nivolumab monotherapy benefits patients who have an acceptable safety profile.
Ablative therapy is an important treatment option for achieving a cancer-free state as HCC rates continue to rise.
Researchers found that patients with diabetes and higher alpha-fetoprotein had decreased OS rates.
Patients randomly received either TACE plus durvalumab and bevacizumab, TACE plus durvalumab, or TACE alone.
In patients with HCC, a high CD8 and low TIM3 expression is linked to better OS than PD-1/PD-L1.
Dr. Elizabeth Conner offers insight on how DCP can be utilized as a biomarker for treatment response in patients with HCC.
Dr. Brown discussed the results of a retrospective analysis on the addition of radiation to atezolizumab and bevacizumab.
Durvalumab plus bevacizumab with TACE demonstrated significantly improved PFS rates over TACE monotherapy.
In 35 patients, the Eastern Cooperative Oncology Group performance status (ECOG-PS) was 0.
An analysis of demographic, clinical characteristics, and treatment patterns for HCC for defining early-stage disease.
A retrospective review offers insights into the safety and efficacy of adding CDDP to lenvatinib for patients with aHCC.
Of the 1115 patients, 83.2% were male, 49.1% were current or ex-smokers, and 21.4% had consumed alcohol.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.